Bio Techne Stock Current Liabilities
T1CH34 Stock | 13.44 1.06 7.31% |
Bio Techne fundamentals help investors to digest information that contributes to Bio Techne's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Techne's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Techne stock.
Bio |
Bio Techne Company Current Liabilities Analysis
Bio Techne's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
In accordance with the recently published financial statements, Bio Techne has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all Brazil stocks is 100.0% higher than that of the company.
Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
All Next | Launch Module |
Bio Fundamentals
Return On Equity | 0.15 | |||
Return On Asset | 0.0771 | |||
Profit Margin | 0.23 % | |||
Operating Margin | 0.26 % | |||
Current Valuation | 73.29 B | |||
Shares Outstanding | 4.72 B | |||
Price To Book | 7.19 X | |||
Price To Sales | 65.05 X | |||
Revenue | 1.11 B | |||
Gross Profit | 758.09 M | |||
EBITDA | 413.76 M | |||
Net Income | 272.05 M | |||
Total Debt | 243.41 M | |||
Book Value Per Share | 0.38 X | |||
Cash Flow From Operations | 325.27 M | |||
Earnings Per Share | 0.28 X | |||
Number Of Employees | 3 K | |||
Beta | 1.21 | |||
Market Capitalization | 60.28 B | |||
Total Asset | 2.29 B | |||
Annual Yield | 0 % | |||
Net Asset | 2.29 B | |||
Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bio Stock
Bio Techne financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Techne security.